Sex: U
Vaccine: RSV
Symptoms: Mass, Neoplasm, Pain, Pain in extremity, Peripheral swelling
Clinical narrative: effusion in the popliteal region; behind my leg a tumor formed; It was red and then it turned purple; mass; hematoma hematoma in the popliteal region; had a lot of pain; leg swallen; ankles were also swollen; left leg began to hurt; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of leg pain in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   Previously administered products included COVID vaccine with an associated reaction of no adverse event (On 18th March 2021, received first dose of vaccine with batch number EN6199 and have not had any problems.), COVID-19 vaccine (On 7th April 2021, received second dose with batch number ER8737), COVID-19 vaccine (On 11th December 2021 received third dose with batch number  S58762) and Zoster vaccine (On an unknown date received shingles vaccine.). Concurrent medical conditions included thrombocytosis, hypothyroidism and cholesterol.   On 18-JAN-2024, the patient received Arexvy. On 24-JAN-2024, 6 days after receiving Arexvy, the patient experienced leg pain (Verbatim: left leg began to hurt). On 27-JAN-2024, the patient experienced swelling of legs (Verbatim: leg swallen), ankle swelling (Verbatim: ankles were also swollen) and pain (Verbatim: had a lot of pain). On an unknown date, the patient experienced effusion (Verbatim: effusion in the popliteal region), neoplasm (Verbatim: behind my leg a tumor formed), erythema (Verbatim: It was red and then it turned purple), mass (Verbatim: mass) and hematoma (Verbatim: hematoma hematoma in the popliteal region). The outcome of the leg pain, swelling of legs, ankle swelling and pain were unknown and the outcome of the effusion was not resolved and the outcome of the neoplasm, erythema, mass and hematoma were not reported.   It was unknown if the reporter considered the leg pain, swelling of legs, ankle swelling, effusion, neoplasm, pain, erythema, mass and hematoma to be related to Arexvy.     It was unknown if the company considered the leg pain, swelling of legs, ankle swelling, effusion, neoplasm, pain, erythema, mass and hematoma to be related to Arexvy.   Additional Information: GSK Receipt Date: 26-FEB-2024 Reporter was a patient. Patient reported that after receiving Arexvy vaccine patient's left leg began to hurt, , it became swollen and patient's  ankles were also swollen like two ping pong balls. Patient had an effusion in the popliteal region, it was red and then it turned purple and behind my leg a tumor formed. Patient still had the effusion marks, but they were now clear. Under patient's ankles also had a very dark, black effusion.  Patient also had a lot of pain, felt heartbeat in legs. Patient went three times to emergency room. Patient reported that clots or fractures were ruled out. Doctor infiltrated knee and they sent patient to rest. Patient suffer from thrombocytosis. Patient had had all of the pfizer covid vaccines and had not had any problems. Patient received three doses of covid vaccine, pneumonia vaccine in September 2023 and shingles vaccine before receiving Arexvy vaccine. Patient had thrombocytosis, thyroid problems and a cholesterol issue, clarified had hypothyroidism and was taking Levotirotrotrinyn, the spelling of the medication Levotirotrotrinyn was captured as provided by the patient and interpreter.  Reporter was asked for the dates of when the cholesterol issue and the hypothyroidism began and did not provide an answer to this question. States for the reported events, had an magnetic resonance imaging and the physical therapy, for the magnetic resonance imaging, stated that the results were there was no clots no thrombus only a mass and the mass which has fluid like a hematoma in the popliteal region. The follow-up could not possible as no contact details were provided.